OR Royalties (OR) – Investment Analysts’ Weekly Ratings Changes

OR Royalties (NYSE: OR) recently received a number of ratings updates from brokerages and research firms:

• 7/24/2026 – OR Royalties was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 7/14/2026 – OR Royalties had its price target lowered by Scotiabank from $51.00 to $42.00. They now have a “sector perform” rating on the stock.
• 7/13/2026 – OR Royalties was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/9/2026 – OR Royalties had its price target lowered by Royal Bank Of Canada from $50.00 to $45.00. They now have an “outperform” rating on the stock.
• 7/6/2026 – OR Royalties had its price target lowered by Jefferies Financial Group Inc. from $40.00 to $34.00. They now have a “hold” rating on the stock.
• 6/6/2026 – OR Royalties was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/4/2026 – OR Royalties was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.

OR Royalties Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th were given a $0.065 dividend. This is an increase from OR Royalties’s previous quarterly dividend of $0.06. This represents a $0.26 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Tuesday, June 30th. OR Royalties’s payout ratio is currently 18.66%.

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.